**Conflict of interest**

The LUMC is the holder of patent application PCT/NL2014/050549, which describes the potential clinical use of CRB2; JW is listed as inventor on this patent, and JW is an employee of the LUMC.

[7] Sanofi-Genzyme. Safety and Tolerability Study of AAV2- sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). [Internet]. 2016. Available

AAV-Mediated Gene Therapy for *CRB1*-Hereditary Retinopathies

http://dx.doi.org/10.5772/intechopen.79308

[8] Feuer WJ, Schiffman JC, Davis JL, Porciatti V, Gonzalez P, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: Initial results. Ophthalmology. 2016;

[9] Ghazi NG, Abboud EB, Nowilaty SR, Alkuraya H, Alhommadi A, Cai H, et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: Results of a phase I trial. Human Genetics. 2016;

[10] Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, et al. Optimization of retinal gene therapy for X-linked retinitis Pigmentosa due to RPGR mutations. Molecular

[11] Pang JJ, Boye SL, Kumar A, Dinculescu A, Deng W, Li J, et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEβ mutation.

[12] Choi VW, Bigelow CE, McGee TL, Gujar AN, Li H, Hanks SM, et al. AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice.

[13] Ou J, Vijayasarathy C, Ziccardi L, Chen S, Zeng Y, Marangoni D, et al. Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer. The Journal of

[14] Janssen A, Min SH, Molday LL, Tanimoto N, Seeliger MW, Hauswirth WW, et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Molecular Therapy. 2008;**16**(6):1010-1017

[15] Pellissier LP, Hoek RM, Vos RM, Aartsen WM, Klimczak R, Hoyng S, et al. Specific tools for targeting and expression in Müller glial cells. Molecular Therapy - Methods &

[16] Pellissier LP, Quinn PM, Alves CH, et al. Gene therapy into photoreceptors and Müller glial cells restores retinal structure and function in CRB1 retinitis pigmentosa mouse

[17] Le Meur G, Lebranchu P, Billaud F, Adjali O, Schmitt S, Bézieau S, et al. Safety and longterm efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital Amaurosis.

[18] Weleber RG, Pennesi ME, Wilson DJ, Kaushal S, Erker LR, Jensen L, et al. Results at 2 years after gene therapy for RPE65-deficient Leber congenital Amaurosis and severe

early-childhood–onset retinal dystrophy. Ophthalmology. 2016;**123**(7):1606-1620

Investigative Ophthalmology and Visual Science. 2008;**49**(10):4278-4283

Molecular Therapy - Methods & Clinical Development. 2015;**2**:15022

from: http://clinicaltrials.gov/ct2/show/NCT01024998 [Accessed: 2018-03-21]

**123**(3):558-570

**135**(3):327-343

Therapy. 2017;**25**(8):1866-1880

Clinical Investigation. 2015;**125**(7):2891-2903

Clinical Development. 2014;**1**(2):14009

Molecular Therapy. 2018;**26**(1):256-268

models. Human Molecular Genetics. 2015;**24**(2):1-15
